Prime

Uganda’s Cipla takes bold step to make ‘unpopular’ malaria drug

Quality Chemical Industries Uganda drug production line in Kampala. PHOTO | MORGAN MBABAZI

By  Julius Barigaba

Reporter in Kampala, Uganda

Nation Media Group

Uganda pharmaceutical firm, Cipla Quality Chemicals Industries Ltd (CiplaQCIL), is taking a big bet in the war against global Covid-19 pandemic.

The Uganda Securities Exchange (USE)-listed company will this month start production of the controversial anti-malarial drug, hydroxychloroquine, targeting Ugandan coronavirus patients and wider African market.

Be the First to Know

Get the stories shaping East Africa — delivered straight to your inbox

Conflict

  1. PRIME Sudan war controversy clouds Lana Nusseibeh's late charge for UN top job

  2. PRIME Kenya, Tanzania face pushback on mandatory travel insurance

  3. Tigray

    PRIME US sidelines TPLF as it seeks to mediate Ethiopia–Eritrea dispute

  4. Sudan's currency tumbles to new low as war hammers economy

Latest

  1. PRIME Ruto’s campaign pitch shifts from ‘Hustler’ to ‘Equality’ ahead of 2027

  2. PRIME African Union silent as Egypt sends troop to Somalia

  3. PRIME Tourism players bank on tighter Ebola screening to rescue high season

  4. PRIME Russia unveils $53m military support package for Uganda

In the headlines

View All